Medical Affairs and Scientific Communications Forum

This event is now offered in a new entirely virtual format.

Back to Agenda

The Mysterious Regulatory Landscape in China: a Medical Writer’s Perspective

Session Chair(s)

Ruggero Galici, PhD

Director, Nonclinical and Clinical Pharmacology Writing

Alexion Pharmaceuticals, AstraZeneca Rare Disease, United States

This session will provide an overview of the dynamic regulatory environment to support the clinical development of pharmaceutical products in China. Preparation of common and unique medical writing documents to support regulatory submissions will be discussed.

Learning Objective :
At the conclusion of this session, participants should be able to:

Discuss the Chinese regulatory environment for pharmaceuticals

Recognize common and unique requirements for regulatory submissions to the Chinese National Medical Products Administration (NMPA)

Identify specific clinical documents for submissions to the NMPA

Speaker(s)

The Mysterious China Regulatory Environment: Considerations in Clinical Development, Regulatory Submissions, and Medical Writing in China

Hongbo Zhu, PhD

Pfizer, Inc., China

Have an account?